 Kaleido Biosciences Inc NASDAQ: KLDO reported positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19. KB109 demonstrated an overall favorable safety and tolerability profile with no unexpected treatment-related adverse events. 